IN8bio, Inc. (INAB) stock
INABNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.82+0.00 (+0.49%)
Close on Nov 17, 2026Market cap $8.08MP/E –Yield –
Earnings
IN8bio's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Mar 11, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$0.24
-$0.85 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of IN8bio's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 11, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 5, 2026after the close | – | – | -$0.24 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 6, 2026during market hours | – | – | -$0.25 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 7, 2026during market hours | – | – | -$0.26 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 12, 2026during market hours | – | – | -$0.45 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 6, 2025during market hours | – | – | -$0.85 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 7, 2025during market hours | – | – | -$1.24 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 7, 2025during market hours | – | – | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 13, 2025during market hours | – | – | -$0.08 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 12, 2024during market hours | – | – | -$0.15 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 8, 2024during market hours | – | – | -$0.19 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 9, 2024during market hours | – | – | -$0.20 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 14, 2024during market hours | – | – | $0.22 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 9, 2023during market hours | – | – | -$0.23 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 10, 2023during market hours | – | – | -$0.27 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 12, 2023before the open | – | – | -$0.30 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 30, 2023during market hours | – | – | -$0.32 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 10, 2022before the open | – | – | -$0.34 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 12, 2022during market hours | – | – | -$0.38 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 12, 2022before the open | – | – | -$0.33 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 17, 2022during market hours | – | – | -$0.44 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 10, 2021during market hours | – | – | -$0.25 | Release |
| Q2 FY2021ended Jun 30, 2021 | Sep 10, 2021during market hours | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
IN8bio has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When IN8bio puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases IN8bio filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- News
- Results
- News
- Results
- News
- Results
- News
- News
- News
- News
See a number that looks wrong?